Lilly to invest US$ 3 bn in China to boost supply of new obesity drug; Servier acquires Day One Biopharma for US$ 2.5 bn
In Phispers this week, Eli Lilly announced its plans to invest US$
3 billion in China over the next decade in order to build p...
Impressions : 2555
US exits WHO; Moderna to stop investing in new late-stage vaccine trials due to increased opposition to immunizations
Public health suffered several setbacks over the last week. First,
the United States formally exited the World Health Organiza...
Impressions : 1995
J&J’s 2026 sales may cross US$ 100 bn; FDA delays fast-track reviews of drugs under Trump’s voucher program
In 2022, Pfizer had crossed US$ 100 billion in revenue owing to its Covid products. While that was a one-off, Johnson & Johnson...
Impressions : 1758
Pfizer seals up to US$ 10 bn deal for Metsera; FDA lifts black box warning on hormone therapies for menopause
In Phispers this week, Pfizer won its high stakes battle with Novo
Nordisk for the obesity-focused biotech Metsera. The deal i...
Impressions : 1485
Sanofi gets two bids valuing its consumer unit at US$ 17 bn; Pfizer pulls SCD drug from market
In news this week, Sanofi is considering the sale of its consumer
health unit and has received binding bids valuing the divisi...
Impressions : 1512
European Study highlights reliance on Asia for APIs; Mallinckrodt files for bankruptcy in US
This week, along with updates on the ongoing pandemic, Phispers brings you news on the opioid epidemic cases in the US, and on ...
Impressions : 62105
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.